سعر تالزينا 0.25 مجم 30 كبسولة 2026

Talazoparib 0.25 mg hard capsules (Pfizer), an oral poly (ADP-ribose) polymerase (PARP) inhibitor.

• Single agent for deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.Population: AdultsDailyMed (U.S. National Library of Medicine)
• In combination with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=20%, single agent): decreased hemoglobin, neutrophils, lymphocytes and platelets, fatigue, increased glucose, AST, ALT and alkaline phosphatase, decreased calcium, nausea, headache, vomiting, alopecia, diarrhea, decreased appetite.International label, same product · DailyMed (U.S. National Library of Medicine)

• None stated in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Myelodysplastic syndrome/acute myeloid leukemia, including fatal cases; monitor and discontinue if confirmed.International label, same product · DailyMed (U.S. National Library of Medicine)
• Myelosuppression: anemia, neutropenia and/or thrombocytopenia.International label, same product · DailyMed (U.S. National Library of Medicine)
• Embryo-fetal toxicity: can cause fetal harm; use effective contraception.International label, same product · DailyMed (U.S. National Library of Medicine)

• P-gp inhibitors (itraconazole, amiodarone, carvedilol, clarithromycin, verapamil)Increase talazoparib exposure; avoid, or reduce the talazoparib dose if unavoidable (breast cancer).DailyMed (U.S. National Library of Medicine)
• BCRP inhibitorsMonitor for increased adverse reactions.DailyMed (U.S. National Library of Medicine)

• Can cause embryo-fetal harm based on animal findings and mechanism; no human data. Fetal malformations and embryo-fetal death in rats at exposures below human exposure.International label, same product · DailyMed (U.S. National Library of Medicine)
• Advise not to breastfeed during treatment and for 1 month after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)